Motley Fool Asset Management LLC Raises Stock Holdings in McKesson Corporation $MCK

Posted by Geri Gentry on Jun 10th, 2026

Motley Fool Asset Management LLC lifted its holdings in McKesson Corporation (NYSE:MCK – Free Report) by 33.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 11,491 shares of the company’s stock after purchasing an additional 2,904 shares during the period. Motley Fool Asset Management LLC’s holdings in McKesson were worth $9,426,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Portfolio Design Labs LLC increased its holdings in McKesson by 3.5% during the 4th quarter. Portfolio Design Labs LLC now owns 3,257 shares of the company’s stock worth $2,672,000 after purchasing an additional 110 shares during the period. Insight Advisors LLC PA increased its holdings in McKesson by 10.9% during the 4th quarter. Insight Advisors LLC PA now owns 294 shares of the company’s stock worth $241,000 after purchasing an additional 29 shares during the period. Stonebrook Private Inc. purchased a new position in McKesson during the 4th quarter worth $212,000. Pettyjohn Wood & White Inc. increased its holdings in McKesson by 22.2% during the 4th quarter. Pettyjohn Wood & White Inc. now owns 325 shares of the company’s stock worth $267,000 after purchasing an additional 59 shares during the period. Finally, Marks Group Wealth Management Inc purchased a new position in McKesson during the 4th quarter worth $609,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Thomas L. Rodgers sold 699 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total transaction of $513,953.73. Following the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,667,592.36. This trade represents a 23.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $2,701,869.50. Following the sale, the executive vice president directly owned 3,247 shares in the company, valued at $2,471,259.23. This trade represents a 52.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 6,893 shares of company stock valued at $5,225,385. 0.08% of the stock is currently owned by corporate insiders.

McKesson Trading Up 2.2%

Shares of NYSE MCK opened at $783.71 on Wednesday. The stock has a market capitalization of $94.20 billion, a PE ratio of 20.37, a price-to-earnings-growth ratio of 1.26 and a beta of 0.31. The stock’s fifty day simple moving average is $802.84 and its two-hundred day simple moving average is $847.76. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.56 by $0.13. The business had revenue of $96.30 billion for the quarter, compared to analysts’ expectations of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same quarter last year, the firm earned $10.12 EPS. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, equities analysts predict that McKesson Corporation will post 44.28 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s dividend payout ratio (DPR) is 8.53%.

Analyst Ratings Changes

Several research analysts have commented on MCK shares. Wells Fargo & Company reduced their price objective on McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Citigroup reduced their price objective on McKesson from $975.00 to $945.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Barclays raised their price objective on McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. UBS Group raised their price objective on McKesson from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. reduced their price objective on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $968.87.

Read Our Latest Research Report on McKesson

McKesson Company Profile

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.